HCV Reactivation Doesn't Worsen Survival in HIV+ Lymphoma Patients

the Cancer Therapy Advisor take:

Results from a new study presented at ASCO 2014 indicate that reactivation of the hepatitis C virus (HCV) in HIV-positive patients with lymphoma does not worsen survival outcomes. For the study, researchers analyzed medical records of 190 HIV-positive patients diagnosed with lymphoma, 28% of whom were also infected with HCV. Reactivation of the virus occurred in about one-third of the patients with HCV, the researchers reported. Overall survival in those co-infected with HCV was 59.7 months versus 88.6 months for patients without HCV or hepatitis B virus. This difference, however, disappeared after adjustment for covariates. No significant association between overall survival and HCV virus in patients with lymphoma was found, according to the data. The researchers hope that this information will help clinical trials expand to include patients with HIV and HCV so that this unique patient population can be better understood.

HCV Reactivation Doesn't Worsen Survival in HIV+ Lymphoma Patients

More than a quarter of HIV+ patients are also infected with the Hepatitis C virus (HCV), which may complicate treatment and care decisions after a cancer diagnosis. Barta, MD, MS, MRCP - who led the study - analyzed data from HIV+ patients diagnosed with lymphoma, collected over 17 years, to better understand how HCV infection influences survival outcomes.

CancerTherapyAdvisor.com is a free online resource that offers oncology healthcare professionals a comprehensive knowledge base of practical oncology information and clinical tools to assist in making the right decisions for their patients.

Our mission is to provide practice-focused clinical and drug information that is reflective of current and emerging principles of care that will help to inform oncology decisions.